Off-the-shelf NK Cells (KDS-1000) as Immunotherapy for COVID-19

"Non-randomized part of study:~* At the beginning of each dose level (Cohort), 3 patients will receive KDS-1000. These initial patients will be enrolled in a staggered manner to ensure detection of any early safety signals.~Randomized part of the study (Can start when there are no safety concerns in the non-randomized cohorts):~* Cohort 1: Low Dose, 2x10E8 cells/dose~* Cohort 2: High Dose, 1x10E9 cells/dose"

0.9% Normal Saline